Matteo Lambertini, Associate Professor at the University of Genova, shared on X:
“Oral abstract Breast Cancer session at ESMO26: very promising data with the bispecific anti-HER2 antibody anbenitamab plus an experimental taxane HB1801 as first-line therapy in advanced HER2+ disease.”
See gallery below.
You can also read: Anbenitamab Plus HB1801 Improves Pathologic Complete Response in HER2-Positive Early Breast Cancer.
